In this issue:
Plasma genotyping for osimertinib in EGFR-mutant NSCLC
ALK variant status might affect ALK-TKI efficacy
Gefitinib vs erlotinib in previously treated advanced lung adenocarcinoma
Gefitinib ± pemetrexed in advanced, EGFR-mutant, nonsquamous NSCLC
Nivolumab + platinum-based doublet chemotherapy in advanced NSCLC
Nivolumab monotherapy in advanced NSCLC
Irinotecan-containing regimen vs topotecan as 2nd-line in SCLC
Consider pemetrexed in RET-rearranged lung cancers?
Please login below to download this issue (PDF)